Search research articles
Contact Us
Filters
Showing results (111-120 of 118) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 118 results.
British Journal of Cancer
|
August 8, 2013
Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer
C Grimm, G Hofstetter, S Aust, et al.
Cancer
|
October 3, 2000
The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma: a multicenter study
L A Hefler, A C Rosen, A H Graf, et al.
British Journal of Cancer
|
February 9, 2012
Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial
V Seebacher, S Polterauer, C Grimm, et al.
British Journal of Cancer
|
January 25, 2007
In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
D Pils, A Pinter, J Reibenwein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 7, 2011
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
L Gladieff, A Ferrero, G De Rauglaudre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
J Sehouli, R Chekerov, A Reinthaller, et al.
Gynecologic Oncology
|
November 24, 2018
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12
F Heitz, P Harter, E Åvall-Lundqvist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2018
Safety and dose modification for patients receiving niraparib
J S Berek, U A Matulonis, U Peen, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 118) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 118 results.
British Journal of Cancer
|
August 8, 2013
Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer
C Grimm, G Hofstetter, S Aust, et al.
Cancer
|
October 3, 2000
The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma: a multicenter study
L A Hefler, A C Rosen, A H Graf, et al.
British Journal of Cancer
|
February 9, 2012
Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial
V Seebacher, S Polterauer, C Grimm, et al.
British Journal of Cancer
|
January 25, 2007
In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
D Pils, A Pinter, J Reibenwein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 7, 2011
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
L Gladieff, A Ferrero, G De Rauglaudre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
J Sehouli, R Chekerov, A Reinthaller, et al.
Gynecologic Oncology
|
November 24, 2018
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12
F Heitz, P Harter, E Åvall-Lundqvist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2018
Safety and dose modification for patients receiving niraparib
J S Berek, U A Matulonis, U Peen, et al.
Page
of 12